Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: A community setting-based trial

Osteoporosis International

Volumn 23, Issue 3, 2012, Pages 1069-1074

  Silverman, S L ^a,b   Nasser, K ^b   Nattrass, S ^c   Drinkwater, B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Osteoporosis Medical Center   (United States)

^c Puget Sound Osteoporosis Center   (United States)

Author keywords

Adherence; Bone turnover markers; N Telopeptide; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE TURNOVER; COMMUNITY TRIAL; CONTROLLED STUDY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COMMUNITY HEALTH SERVICES; DRUG ADMINISTRATION SCHEDULE; FEEDBACK, PSYCHOLOGICAL; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT EDUCATION AS TOPIC; UNITED STATES;

EID: 84857444819     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1721-z     Document Type: Article

References (16)

1. S Silverman JR Schein 2001 Physician-patient decision making in osteoporosis management J Musculoskel Med 18 124 130
2. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 12 1493 1501 18053457 10.4065/82.12.1493 (Pubitemid 350211697)
3. SM Rubin SR Cummings 1992 Results of bone density information affect women's decisions about taking measures to prevent fractures Ann Intern Med 116 990 995 1586110 1:STN:280:DyaK383msVKnug%3D%3D
4. S Silverman B Drinkwater 1997 Effect of bone density information on decision making about estrogen Obstet Gynecol 89 321 325 9052578 10.1016/S0029-7844(97)85857-7 1:CAS:528:DyaK2sXhsl2msLY%3D (Pubitemid 27090343)
5. SR Cummings L Palermo W Browner, et al. 2000 Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean JAMA 283 1318 10714731 10.1001/jama.283.10.1318 1:STN:280:DC%2BD3c7nslaisQ%3D%3D
6. A Papanioannou W Parkinson J Adachi, et al. 1998 Women's decisions about taking measures to prevent fractures Can Med Assoc J 15 10 1253 1257
7. T Gleeson MD Iversen J Avorn AM Brookhart JN Katz E Losina F May AR Patrick WH Shrank DH Solomon 2009 Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Osteoporos Int 20 2127 2134 10.1007/s00198-009-0976-0 19499273 10.1007/s00198-009-0976-0 1:STN:280:DC%2BC3c7mslOqtQ%3D%3D
8. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123 15001596 10.1210/jc.2003-030501 1:CAS:528:DC%2BD2cXisVWrtbo%3D (Pubitemid 38368399)
9. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe A Grauer D Cahall NB Watts Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 17244788 10.1210/jc.2006-1526 1:CAS:528:DC%2BD2sXksVSrsbc%3D (Pubitemid 46556401)
10. Physician's guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C.
11. L Fraenkel B Gulanski D Wittink 2007 Patient willingness to take teriparatide Patient Educ Couns 65 2 237 244 16965888 10.1016/j.pec.2006.08.004 (Pubitemid 46073565)
12. J Ratcliffe M Buxton T McGarry R Sheldon J Chancellor 2004 Patients' preferences for characteristics associated with treatments for osteoarthritis Rheumatology 43 337 345 14585925 10.1093/rheumatology/keh038 1:STN:280:DC%2BD2c%2FnsVGisw%3D%3D (Pubitemid 38313184)
13. M Potts M Weinberger KD Brandy 1984 Views of patients and providers regarding the importance of various aspects of an arthritis treatment program J Rheumatol 11 71 75 6699836 1:STN:280:DyaL2c7jvVClsA%3D%3D (Pubitemid 14172146)
14. L Fraenkel B Gulanski D Wittink 2006 Patient treatment preferences for osteoporosis Arthritis Rheum 55 5 729 735 17013870 10.1002/art.22229 (Pubitemid 44619186)
15. V Rabenda R Mertens V Fabri, et al. 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 10.1007/s00198-007-0506-x 17999022 10.1007/s00198-007-0506-x 1:CAS:528:DC%2BD1cXltFyjurs%3D
16. D Weycker D Macarios J Edelsberg G Oster 2006 Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645 1652 10.1007/s00198-006-0179-x 16862397 10.1007/s00198-006-0179-x 1:STN:280:DC%2BD28rotlahsA%3D%3D (Pubitemid 44477625)